Compare SkyWest Inc (SKYW) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? SkyWest Inc trades at $96 (market cap $3.75B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 15.7× SkyWest Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SkyWest Inc for 8 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SKYW | TAK | |
|---|---|---|
Market Cap | $3.75B | $58.74B |
Volume | 196,324 | 3,110,994 |
Sector | Industrials | Health |
52-Week High | $115.94 | $19.05 |
52-Week Low | $78.40 | $13.23 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | $5.54B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with revenue growth from $4.1B in 2025 to $4.2B in 2026. Analyst consensus is bullish with a $112 price target, supported by fleet upgrades and flying agreements, though net income margin dipped to 9.78% in 2026.
The outlook is cautiously optimistic given strong analyst buy ratings and undervalued metrics like a P/E of 9.6, but risks include cost pressures, insider selling, and technical bearishness. Upside hinges on execution of growth initiatives amid competitive and operational headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
